Copyright 2016 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.
To the Editor Ms Hua and colleagues1 compared 2002-2013 trends in diabetes drug expenditures, particularly insulins, using the Medical Expenditure Panel Survey (MEPS). We note important limitations to their analysis and conclusions. The findings revealed recent dynamic changes in insurance benefit design as higher cost exposure shifts to consumers, but the authors overstated price and did not consider significant changes in diabetes care and the US insurance landscape during the study period.
Alatorre C, Schultz EH, Nelson DR. Cost of Antihyperglycemic Medications in the United States. JAMA. 2016;316(6):665. doi:10.1001/jama.2016.8587
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: